This study reveals a novel mechanism by which PirB is cleaved by MMPs under Aβ pathology and disrupts Golgi trafficking, offering fresh insights for drug target screening and intervention strategies in Alzheimer's disease, suggesting that targeting the PirB-GGA3 interaction interface may restore neuronal membrane trafficking function.
Literature Overview
This paper, 'Persistent PirB cleavage drives Golgi-directed trafficking deficits underlying neurodegeneration,' published in the journal Translational Neurodegeneration, systematically investigates the non-canonical signal transduction mechanisms of the neuroimmune receptor PirB in Alzheimer's disease (AD). By integrating human cerebrospinal fluid proteomics, transgenic mouse models, and primary neuronal functional experiments, the authors discovered that Aβ-induced PirB proteolysis not only activates its extracellular functions but also generates a C-terminal fragment (PirB-CTF) that enters the cell and interferes with Golgi trafficking, thereby directly coupling immune receptor activation to organelle dysfunction. This finding expands our understanding of receptor proteolytic reprogramming in AD and identifies a new therapeutic target.Background Knowledge
The core pathological features of Alzheimer's disease (AD) include Aβ plaque deposition and hyperphosphorylation of tau protein, accompanied by widespread neuronal degeneration and cognitive decline. In recent years, neuroimmune receptors such as TREM2 and PirB have been found to participate in AD progression, but how they convert extracellular pathological signals into intracellular dysfunction remains unclear. As the murine homolog of LILRB2, PirB binds to MHC-I and Aβ oligomers and is believed to play roles in synaptic pruning and neuroinflammation. However, whether it undergoes ligand-dependent cleavage and whether its cleavage products possess independent functions remain unexplored. Current therapies targeting Aβ or tau have shown limited clinical success, highlighting the need to deeply analyze downstream signaling pathways. This study, based on the non-canonical mechanism of 'receptor proteolytic reprogramming,' proposes that PirB cleavage may serve as a key node in AD signal transduction, thereby bridging the mechanistic gap between immune recognition and organelle dysfunction.
Research Methods and Experiments
The authors first used human cerebrospinal fluid proteomic data combined with bioinformatic analysis to screen for membrane protein cleavage events enriched in AD patients, identifying LILRB2 (i.e., PirB) as a potential substrate. Subsequently, in AD patient brain tissues and the APP/PS1 mouse model, they confirmed the accumulation of the PirB C-terminal fragment (PirB-CTF) via immunoprecipitation and mass spectrometry. To investigate the cleavage mechanism, the authors constructed multiple PirB mutants and used MMP inhibitors (e.g., GM-6001) and γ-secretase inhibitors (DAPT), confirming that PirB is cleaved by MMPs upon Aβ stimulation, with the cleavage product further processed by γ-secretase. Using subcellular fractionation and immunofluorescence colocalization, the authors found that PirB-CTF localizes to the Golgi apparatus via retrograde transport rather than remaining at the plasma membrane.
Furthermore, using live-cell imaging with the RUSH system, Duolink PLA, and GST pull-down assays, the authors revealed that PirB-CTF specifically binds to the GAT domain of GGA3, competitively inhibiting GGA3-mediated vesicular trafficking. Functionally, by assessing cathepsin D maturation, axonal transport kymograph analysis, and behavioral tests (e.g., Barnes maze and fear conditioning), the authors demonstrated that PirB cleavage leads to impaired lysosomal maturation, defective synaptic vesicle trafficking, and memory deficits. Finally, by overexpressing GGA3-GAT or blocking PirB cleavage in APP/PS1 mice, the authors successfully restored Golgi function, reduced Aβ plaques and tau phosphorylation, and improved cognitive performance, validating the therapeutic potential of this pathway.Key Conclusions and Perspectives
Research Significance and Prospects
This study challenges the traditional view that immune receptors only affect neuroinflammation through extracellular signaling, proposing that the PirB cleavage product acts as an intracellular 'disruptor' that directly interferes with Golgi function, providing a new dimension to AD pathogenesis. This finding emphasizes the signal-amplifying role of proteolytic events in neurodegenerative diseases, suggesting that future drug development should consider targeting receptor cleavage processes or their downstream effectors.
From a drug development perspective, the PirB-CTF/GGA3 interaction interface is a highly promising target, where small-molecule inhibitors or peptide antagonists may restore membrane trafficking homeostasis. In terms of clinical monitoring, PirB-CTF levels in cerebrospinal fluid could serve as a biomarker for early membrane trafficking dysfunction. Additionally, this mechanism may apply to other neurodegenerative diseases such as Parkinson’s disease or frontotemporal dementia, promoting the development of more precise disease modeling systems.
Conclusion
This study systematically reveals the complete pathway in which PirB is cleaved by MMPs upon Aβ stimulation to generate PirB-CTF, which then binds to GGA3 and disrupts Golgi trafficking, ultimately leading to lysosomal dysfunction and neuronal degeneration. This mechanism directly couples neuroimmune recognition with organelle dysfunction, providing a novel molecular explanation for AD pathology. From bench to bedside, targeting PirB cleavage or the PirB-CTF/GGA3 interaction interface holds promise as a new strategy to combat cognitive decline in AD. This discovery not only expands our understanding of AD pathogenesis but also provides a paradigm for membrane trafficking research in other neurodegenerative diseases. Future development of biomarkers and small-molecule screening based on this pathway will accelerate the implementation of precision medicine in neurodegenerative disorders, serving as a crucial cornerstone for improving patient care systems.
